/ZURA
ZURA Stock - Zura Bio Limited
Healthcare|BiotechnologyNASDAQ
$4.27+0.00%
+$0.00 (+0.00%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-29.7%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ZURA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.23 – $4.31
TARGET (TP)$3.00
STOP LOSS$3.93
RISK/REWARD1:-3.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.24
52W High$4.68
52W Low$0.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-55,189,000 | $-62,638,000 | $-27,162,000 | $-1,091,986 |
| Net Income | $-52,403,000 | $-60,360,000 | $-25,738,000 | $8.42M |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.60 | $-2.09 | $0.21 | $0.40 |
Company Overview
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
1
14%
Buy / Outperform
5
71%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↑ 271.8% Upside
Now
$5
Low
$16
Average
$26
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2024 | Leerink Partners | Initiation | Outperform | $15 |
| September 5th 2024 | H.C. Wainwright | Initiation | Neutral | $5 |
| May 3rd 2024 | Piper Sandler | Initiation | Overweight | $26 |
| October 10th 2023 | Ladenburg Thalmann | Initiation | Buy | $10 |
| August 25th 2023 | Oppenheimer | Initiation | Outperform | $17 |
| June 22nd 2023 | Guggenheim | Initiation | Buy | $20 |
| June 14th 2023 | Chardan Capital Markets | Initiation | Buy | $14 |
| May 24th 2023 | Raymond James | Initiation | Strong Buy | $20 |
Earnings History & Surprises
ZURABeat Rate
45%
Last 11 quarters
Avg Surprise
-33.2%
EPS vs Estimate
Beats / Misses
5/5
1 met exactly
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
+17.4%
$-0.19vs$-0.23
Q2 24
+91.3%
$-0.02vs$-0.23
Q3 24
-30.8%
$-0.17vs$-0.13
Q4 24
-85.7%
$-0.26vs$-0.14
Q1 25
+50.0%
$-0.08vs$-0.16
Q2 25
-11.8%
$-0.19vs$-0.17
Q3 25
+10.5%
$-0.17vs$-0.19
Q4 25
-10.5%
$-0.21vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.19 | $-0.21 | -10.5% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.16 | $-0.08 | +50.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.14 | $-0.26 | -85.7% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.13 | $-0.17 | -30.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.23 | $-0.02 | +91.3% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.25 | $-0.18 | +28.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.25 | $-1.31 | -424.0% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-2.76 | $-2.76 | 0.0% | = MET |
Q1 2023 | Mar 31, 2023 | — | $-0.27 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.06 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.05 | — | — |
Q1 2022 | Mar 30, 2022 | — | $0.01 | — | — |
Q4 2021 | Dec 30, 2021 | — | $0.05 | — | — |
Q3 2021 | Sep 29, 2021 | — | $0.34 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.00 | — | — |
Latest News
Chardan Capital Maintains Buy on Zura Bio, Maintains $10 Price Target
📈 PositiveBenzinga•Nov 14, 2025, 08:54 PM
Zura Bio Q4 EPS $(0.21) Misses $(0.18) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 11:32 AM
Clear Street Initiates Coverage On Zura Bio with Buy Rating, Announces Price Target of $18
📈 PositiveBenzinga•Nov 13, 2025, 11:12 AM
Zura Bio CEO Robert Lisicki To Take Medical Leave; Kim Davis Appointed Interim CEO
📉 NegativeBenzinga•Oct 10, 2025, 12:24 PM
Chardan Capital Maintains Buy on Zura Bio, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 11:19 AM
HC Wainwright & Co. Maintains Neutral on Zura Bio, Lowers Price Target to $2
➖ NeutralBenzinga•Aug 19, 2025, 10:55 AM
Frequently Asked Questions about ZURA
What is ZURA's current stock price?
Zura Bio Limited (ZURA) is currently trading at $4.27 per share. The stock has moved +0.00% today.
What is the analyst price target for ZURA?
The average analyst price target for ZURA is $3.00, based on 1 analyst.
What sector is Zura Bio Limited in?
Zura Bio Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ZURA's market cap?
Zura Bio Limited has a market capitalization of $0.28 billion, making it a small-cap company.
Does ZURA pay dividends?
No, Zura Bio Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
Explore stocks similar to ZURA for comparison